COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease
Zahidee Rodriguez, Andi L. Shane, Hans Verkerke, Christopher Lough, Matthew G. Zimmerman, Mehul S. Suthar, Jens Wrammert, H. Robson MacDonald, Michael Wolf, Shanelle Clarke, John D. Roback, Connie M. Arthur, Sean R. Stowell, Cassandra D. Josephson
Abstract
Key Points COVID-19 convalescent plasma (CP) may be a safe and effective treatment option in SARS-CoV-2 infection refractory to remdesivir. Infants may benefit from CP despite developing immune systems and donor variability emphasizes the need for characterization prior to use.
Topics & Concepts
Convalescent plasmaCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineRefractory (planetary science)2019-20 coronavirus outbreakVirologyIntensive care medicineHeart diseaseDiseaseImmunologyInternal medicineInfectious disease (medical specialty)BiologyAstrobiologyOutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testing